In the randomised controlled study, around 77% of patients within the efficacy evaluable population who have been treated for around six months with chlormethine gel indicated a clinical response in the composite assessment of index lesion severity score, while 59% of those treated with the compounded control had a clinical response.
Since 2013, the chlormethine gel has been marketed in the US under the brand name Valchlor (mechlorethamine).
Technician Karen Beattie selected Chlormethine
instead of Carmustine while he was being treated for lymphoma.
a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris' investigational drug, chlormethine
gel (also known as mechlorethamine gel in the US), for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
The study demonstrated that 77% of patients who were treated for at least six months with chlormethine
gel achieved a clinical response in the Composite Assessment of Index Lesion Severity (CAILS) score, while 59% of those treated with the compounded control had a clinical response.
M2 PHARMA-January 19, 2012-Ceptaris gets EMA Orphan Drug Designation for chlormethine
gel for CTCL(C)2012 M2 COMMUNICATIONS